翰宇藥業(300199.SZ)：申請專項課題“促性腺激素釋放激素拮抗劑西曲瑞克的研究與開發”獲立項支持
格隆匯7月31日丨翰宇藥業(300199.SZ)公佈，近日，公司收到國家衞生健康委醫藥衞生科技發展研究中心下發的《關於“重大新藥創制”科技重大專項2020年度實施計劃立項課題的通知》(衞科專項函[2019]860號)。公司申請的專項課題《促性腺激素釋放激素拮抗劑西曲瑞克的研究與開發》獲得立項支持。
課題名稱：促性腺激素釋放激素拮抗劑西曲瑞克的研究與開發；課題編號：2020ZX09301022；課題責任單位：深圳翰宇藥業股份有限公司；課題執行期限：2020年1月-2020年12月；課題經費：總經費2002萬元，其中2020年中央財政經費150萬元(事後立項事後補助)。
西曲瑞克是一種人工合成的促性腺激素釋放激素(GnRH)拮抗劑(GnRH-A)藥物，通過與內源性LHRH競爭垂體細胞上的膜受體，從而控制黃體生成素(LH)和卵泡刺激素(FSH)的分泌。對進行控制性卵巢刺激的患者，防止提前排卵，進而進行採卵和輔助生殖技術治療。大量研究表明，西曲瑞克也對卵巢癌、前列腺癌、子宮纖維瘤、子宮內膜異位等疾病有較好的療效，而且對良性前列腺肥大和卵巢過度刺激綜合徵有預防作用。
課題依託“多肽藥物國家地方聯合工程實驗室”技術平台，獨立自主研發，採用自有創新的“多重替代法生產氨基酸樹脂”、“相轉移法生產保護氨基酸”、“固相高效環合技術”、“定序小分子多肽分離”等技術，攻克特殊氨基酸偶聯技術及純化技術難題，突破多肽固相合成規模化生產關鍵性技術。
公司近年持續加大研發投入，積極推進多個重磅產品的研究開發與註冊申報等工作。《促性腺激素釋放激素拮抗劑西曲瑞克的研究與開發》課題被成功列入國家“重大新藥創制”科技重大專項立項課題，是對公司西曲瑞克項目的高度認可。專項課題的實施，有助於強化企業技術創新主體地位，加強研發和科技創新轉化與應用，提升公司自主創新能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
